Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

NCT: NCT06274801 · RECRUITING

NCT IDNCT06274801
StatusRECRUITING
Start Date2024-09-03
Completion2026-12
SponsorGossamer Bio USA, Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

This open-label extension study will evaluate the long-term safety, tolerability and efficacy of orally inhaled seralutinib in subjects who have completed a previous seralutinib study

Frequently Asked Questions

What is Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)?

Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT) is a clinical trial registered under NCT06274801. Current status: RECRUITING.

What is the status of NCT06274801?

The current status of NCT06274801 (Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)) is: RECRUITING.

When did Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT) start?

Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT) started on 2024-09-03.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑